Funding landscape
Where funding for this ecosystem could realistically come from, and the discipline this wiki applies to funding claims.
The rule for this page
A funding page should list only specific calls, each with identifier, eligibility, deadline, source, responsible person, and date checked.
Until specific calls are entered that way, what follows is a search space, not a list of opportunities being pursued. Nothing below should be read as an application in progress.
Search space
| Source | Relevance |
|---|---|
| Horizon Europe Health | The main EU health research instrument |
| WIDERA | EU widening participation and spreading excellence |
| Hop-on facility | Lets a widening-country partner join an already-selected Horizon consortium |
| Twinning | Pairs a widening-country institution with strong international partners — a natural fit for the Copenhagen and Sorbonne connections |
| Simons Foundation / SFARI | Autism research — connects to the autism line rather than the psychiatry line |
| Lundbeck Foundation | Danish; aligns with the Benros connection |
| Hungarian research funding | NKFIH and related instruments — the route that already funded the VSMT trial |
| Industrial collaboration | Direct company-funded work; the historical Richter engagement is the precedent |
Already-secured funding in the ecosystem
| Award | Holder | Note |
|---|---|---|
| NKFIH ADVANCED_25, entry 153443 — Adaptation of Avatar Therapy to BPD: VSMT | Zsolt Unoka, Semmelweis | Start 1 January 2026, 48-month maximum. Supports the avatar-therapy project; Speech Gap integration is under consideration, not a funded component |
| NKFIH Startup Factory — HUF 250M, topped to HUF 284M privately | White Unicorn | For 10–15 early-stage startups; typical ticket HUF 20–30M with co-investment for larger clinical steps |
Safeguard. The VSMT grant’s 31 December 2029 end is the maximum-duration implication of the call terms, not a confirmed contractual end date.
The venture route
Distinct from research funding, and reached through a different door. Erik Szabó’s network already includes technology-transfer offices at Szeged, Pécs, Debrecen and Pannonia, co-investors HunBAN, Lunar Program and Gateway Ventures, and MDR/FDA service providers. Any project taking this route is screened against the five-test framework.
Related pages
Programme opportunities · Ecosystem map · Erik Szabó · Michael E. Benros · MILAB